News & Media

InnoPharma Announces FDA Approval of Decitabine for Injection, a Generic Version of DACOGEN®

Posted on Aug 29, 2014

DOWNLOAD PDF -  Piscataway, N.J., August 29, 2014 – InnoPharma, Inc. today announced the approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for decitabine for injection, a generic version of Eisai Inc.’s DACOGEN®. (more…)

InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada

Posted on Jul 30, 2014

DOWNLOAD PDF  –  Piscataway, N.J., July 30, 2014 – InnoPharma, Inc. today announced the first generic launch of Olanzapine for Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), in Canada. Olanzapine is indicated for the rapid control of agitation and disturbed behaviors in patients with schizophrenia or bipolar I mania.

As the developer of this generic injectable drug, InnoPharma has entered into an agreement with Sandoz Canada Inc., pursuant to which Sandoz Canada will make, use, sell, market and distribute Olanzapine Injection in Canada. (more…)

Pfizer To Acquire InnoPharma,Inc.

Posted on Jul 16, 2014

DOWNLOAD PDF  – NEW YORK, N.Y., and PISCATAWAY, NJ, July 16 – Pfizer Inc. (NYSE: PFE) and InnoPharma, Inc., a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma.

Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments. (more…)

InnoPharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference

Posted on Jan 6, 2014

DOWNLOAD PDF – Piscataway, N.J., January 6, 2014 – InnoPharma, Inc., a privately held company focused on developing first to file and first to market opportunities in the complex generic and specialty pharmaceutical product space, is pleased to announce that it is scheduled to present at the 32nd Annual J.P. Morgan Healthcare Conference at 8:00 am PT on January 15, 2014. The conference will be held at the Westin St. Francis Hotel in San Francisco. (more…)

InnoPharma Inc. Completes $20 Million Term Loan Facility

Posted on Nov 13, 2013

DOWNLOAD PDF – PISCATAWAY, N.J., November 13, 2013 — InnoPharma, Inc today announced that it has closed on a $20 million term loan facility, provided by Athyrium Capital Management through its Athyrium Opportunities Fund. Proceeds will support the Company’s ongoing development of complex generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms. Armentum Partners acted as financial advisors to InnoPharma for this transaction. (more…)